Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells

(2010) Sandrine Reigadas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Recovery of Replication-Competent Residual HIV-1 from Plasma of a Patient Receiving Prolonged, Suppressive Highly Active Antiretroviral Therapy

(2010) G. K. Sahu et al.   JOURNAL OF VIROLOGY

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

(2010) Rajesh T. Gandhi et al.   PLOS MEDICINE

Response to Vicriviroc in Treatment‐Experienced Subjects, as Determined by an Enhanced‐Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211

(2009) Zhaohui Su et al.   JOURNAL OF INFECTIOUS DISEASES

Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy

(2009) T. P. Brennan et al.   JOURNAL OF VIROLOGY

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells

(2008) Gautam K. Sahu et al.   JOURNAL OF MEDICAL VIROLOGY

HIV rebounds from latently infected cells, rather than from continuing low-level replication

(2008) B. Joos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120

(2008) Robert A. Ogert et al.   VIROLOGY

A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients

(2008) Jianqing J. Yu et al.   VIROLOGY